Relapse · SSNS in children
Cyclophosphamide showed no clear difference in relapse at 12 months compared with chlorambucil (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Cyclophosphamide showed no clear difference in relapse at 24 months compared with chlorambucil (low certainty).
1 finding from 1 review
Adverse effects: severe infection · SSNS in children
Rituximab showed no clear difference in adverse effects: severe infection compared with placebo or control (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: lymphopenia · SSNS in children
Cyclophosphamide may leads to lower adverse effects: lymphopenia compared with chlorambucil (low certainty).
1 finding from 1 review
Thrombocytopenia · SSNS in children
Cyclophosphamide may leads to lower adverse effects: thrombocytopenia compared with chlorambucil (low certainty).
1 finding from 1 review
Adverse effects: severe infection · SSNS in children
It is very uncertain whether cyclophosphamide changes adverse effects: severe infection compared with chlorambucil (very low certainty).
1 finding from 1 review
Adverse events: hair loss · SSNS in children
It is very uncertain whether cyclophosphamide changes adverse effects: hair loss compared with chlorambucil (very low certainty).
1 finding from 1 review
Adverse effects: arthropathy · SSNS in children
Rituximab showed no clear difference in adverse effects: arthropathy compared with placebo or control (low certainty).
1 finding from 1 review
Relapse · SSNS in children
Mycophenolate mofetil showed no clear difference in relapses at 12 months compared with levamisole (low certainty).
1 finding from 1 review
AHI · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
AHI · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review